Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

124.47 -0.69 (-0.55%)
Streaming Delayed Price Updated: 3:42 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
News headline image
Opes Wealth Sells Its Entire FIXD Stake -- Is This $9.3 Million Bond ETF Exit A Signal? ↗
This fixed-income ETF offers diversified bond exposure and a flexible strategy focused on income and sector allocation. 
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability ↗
Via Chartmill
Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability ↗
Via Chartmill
News headline image
3 Healthcare Stocks That Pay You While You Wait for the Growth ↗
It may not seem like it at first, but these dividends are safe. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
What's Going On With Arcus Biosciences Stock On Wednesday? ↗
Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declines option extension. 
Via Benzinga
News headline image
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others ↗
Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs. 
Via Investor's Business Daily
News headline image
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
From Gilead Sciences, Inc.
Via Business Wire
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers.... 
Via StockStory
Topics Artificial Intelligence
News headline image
Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries ↗
Tempus AI (TEM) shares up 3.6% on expanded Gilead oncology deal. Explore technical support levels, ALERT trial success, and analyst ratings. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
Via MarketMinute
Topics Bonds
News headline image
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline ↗
Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with data, analytics and drug development. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal ↗
Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook. 
Via Benzinga
News headline image
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,... 
Via MarketMinute
News headline image
Gilead Extends Tender Offer to Acquire Arcellx
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences's Q1 2026 Earnings: What to Expect
Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth. 
Via Barchart.com
Topics ETFs Workforce
News headline image
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution
In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines... 
Via MarketMinute
News headline image
Options Action: Naked Put Trade Ideas for March 31
With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener. 
Via Barchart.com
News headline image
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗
This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition ↗
Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms. 
Via Benzinga
News headline image
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
From Gilead Sciences, Inc.
Via Business Wire
News headline image
The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips
As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.